AbbVie is jumping into the TL1A space, inking a new deal with a Beijing-based biotech.
The company said Thursday that it’s partnering with FutureGen Biopharmaceutical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.